The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia patients 75 years or older, or who have comorbidities that preclude use of standard intensive induction chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Marina Konopleva joins Break Through Cancer

Marina Konopleva, director of the Leukemia Program and co-director of the Blood Cancer Institute at the Montefiore Einstein Comprehensive Cancer Center, has joined Break Through Cancer, a collaborative medical research foundation that supports teams of scientists as they advance treatments for some of the world’s deadliest cancers. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account